All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
In the open-label, multi-center phase III ENDEAVOR trial (NCT01568866) carfilzomib and dexamethasone (Kd56) showed superior progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (RRMM). It is important to evaluate the efficacy and safety of proteasome inhibitors in MM patients with renal impairment as renal failure is a common complication and can lead to dismal outcomes in this patient population. Our steering committee member, Professor Meletios Dimopoulos and colleagues conducted a subgroup analysis of ENDEAVOR to assess the safety and efficacy of Kd56 versus Vd in RRMM patients with varying degrees of renal impairment at randomization. The paper was published in Blood on 10 January 2019.
Data shown as Kd56 versus Vd cohorts
Grade ≥ 3 adverse events
Taken together, Kd56 improved PFS and OS in comparison with Vd in RRMM patients regardless of their baseline renal function. Furthermore, Kd56 showed a favourable safety profile that supports the use of Kd56 as standard of care for RRMM patients with renal impairment.
References
Your opinion matters
Are you currently re-using anti-CD38 therapy in patients with multiple myeloma who have been previously exposed but were not refractory to it?